ascopubs.org

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine ...

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...
TipRanks on MSN

Amgen advances olpasiran heart plaque study, highlighting a growing bet on lipoprotein(a)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Study Overview Amgen is launching a Phase 3 trial ...

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date ...
Pharmabiz

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study: Friendswood, Texas Friday, December 19, 2025, 15:00 H ...
TipRanks on MSN

Organogenesis nears key data milestone with phase 3 knee osteoarthritis study

Organogenesis Holdings ($ORGO) announced an update on their ongoing clinical study. Study Overview Organogenesis Holdings (ORGO) is sponsoring a ...

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: ...